Astellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month High – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares hit a new 52-week high during trading on Saturday . The company traded as high as $14.72 and last traded at $14.08, with a volume of 164352 shares trading hands. The stock had previously closed at $14.22.

Analysts Set New Price Targets

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold”.

Astellas Pharma Trading Down 1.0%

The company has a market capitalization of $25.48 billion, a price-to-earnings ratio of 29.96 and a beta of 0.17. The business has a fifty day moving average price of $13.10 and a 200 day moving average price of $11.56. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.10. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%.The company had revenue of $3.45 billion during the quarter, compared to the consensus estimate of $3.14 billion. On average, equities analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).